Domiciliary diurnal variation of exhaled nitric oxide fraction for asthma control

European Respiratory Journal

Volumn 43, Issue 2, 2014, Pages 474-484

  Saito, Junpei ^a   Gibeon, David ^a   Macedo, Patricia ^a   Menzies Gow, Andrew ^a   Bhavsar, Pankaj K ^a   Chung, Kian Fan ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ASTHMA; BRONCHODILATOR AGENTS; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; EXHALATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MONITORING, AMBULATORY; NITRIC OXIDE; PEAK EXPIRATORY FLOW RATE; QUESTIONNAIRES; RESPIRATORY FUNCTION TESTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SPIROMETRY;

EID: 84893480680     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00048513     Document Type: Article

References (42)

1. Taylor DR, Bateman ED, Boulet LP, et al. A new perspective on concepts of asthma severity and control. Eur Respir J 2008; 32: 545-554.
2. Global Initiative for Asthma. Global strategy for asthma management and prevention (GINA). Available from: www.ginasthma.org Date last updated: December 2012. Date last accessed: September 30, 2013.
3. Zhang J, Yu C, Holgate ST, et al. Variability and lack of predictive ability of asthma end-points in clinical trials. Eur Respir J 2002; 20: 1102-1109.
4. Reddel HK. Peak flow monitoring in clinical practice and clinical asthma trials. Curr Opin Pulm Med 2006; 12: 75-81.
5. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180: 59-99.
6. Thamrin C, Nydegger R, Stern G, et al. Associations between fluctuations in lung function and asthma control in two populations with differing asthma severity. Thorax 2011; 66: 1036-1042.
7. Cazzoletti L, Marcon A, Janson C, et al. Asthma control in Europe: a real-world evaluation based on an international population-based study. J Allergy Clin Immunol 2007; 120: 1360-1367.
8. Rabe KF, Adachi M, Lai CK, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004; 114: 40-47.
9. Peters SP, Jones CA, Haselkorn T, et al. Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national Web-based survey. J Allergy Clin Immunol 2007; 119: 1454-1461.
10. Bateman ED, Reddel HK, Eriksson G, et al. Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol 2010; 125: 600-608.
11. Zeiger RS, Yegin A, Simons FE, et al. Evaluation of the National Heart, Lung, and Blood Institute guidelines impairment domain for classifying asthma control and predicting asthma exacerbations. Ann Allergy Asthma Immunol 2012; 108: 81-87.
12. Bousquet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126: 926-938.
13. Accordini S, Corsico AG, Braggion M, et al. The cost of persistent asthma in Europe: an international populationbased study in adults. Int Arch Allergy Immunol 2013; 160: 93-101.
14. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. Am J Respir Crit Care Med 2011; 184: 602-615.
15. Jones SL, Kittelson J, Cowan JO, et al. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am J Respir Crit Care Med 2001; 164: 738-743.
16. Michils A, Baldassarre S, Van Muylem A. Exhaled nitric oxide and asthma control: a longitudinal study in unselected patients. Eur Respir J 2008; 31: 539-546.
17. Stern G, de Jongste J, van der Valk R, et al. Fluctuation phenotyping based on daily fraction of exhaled nitric oxide values in asthmatic children. J Allergy Clin Immunol 2011; 128: 293-300.
18. Pijnenburg MW, Floor SE, Hop WC, et al. Daily ambulatory exhaled nitric oxide measurements in asthma. Pediatr Allergy Immunol 2006; 17: 189-193.
19. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000; 162: 2341-2351.
20. Juniper EF, O'Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14: 902-907.
21. Juniper EF, Guyatt GH, Epstein RS, et al. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992; 47: 76-83.
22. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338.
23. American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005; 171: 912-930.
24. Roberts G, Hurley C, Bush A, et al. Longitudinal study of grass pollen exposure, symptoms, and exhaled nitric oxide in childhood seasonal allergic asthma. Thorax 2004; 59: 752-756.
25. Pijnenburg MW, Bakker EM, Hop WC, et al. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. Am J Respir Crit Care Med 2005; 172: 831-836.
26. Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med 2005; 172: 453-459.
27. Kharitonov SA, Yates DH, Barnes PJ. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med 1996; 153: 454-457.
28. Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352: 2163-2173.
29. de Jongste JC, Carraro S, Hop WC, et al. Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. Am J Respir Crit Care Med 2009; 179: 93-97.
30. Szefler SJ, Mitchell H, Sorkness CA, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet 2008; 372: 1065-1072.
31. Bodini A, Peroni D, Loiacono A, et al. Exhaled nitric oxide daily evaluation is effective in monitoring exposure to relevant allergens in asthmatic children. Chest 2007; 132: 1520-1525.
32. Volbeda F, Broekema M, Lodewijk ME, et al. Clinical control of asthma associates with measures of airway inflammation. Thorax 2013; 68: 19-24.
33. van der Valk RJ, Baraldi E, Stern G, et al. Daily exhaled nitric oxide measurements and asthma exacerbations in children. Allergy 2012; 67: 265-271.
34. Dennis SM, Sharp SJ, Vickers MR, et al. Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework. Lancet 2000; 355: 1675-1679.
35. Thamrin C, Zindel J, Nydegger R, et al. Predicting future risk of asthma exacerbations using individual conditional probabilities. J Allergy Clin Immunol 2011; 127: 1494-1502.
36. Toogood JH, Andreou P, Baskerville J. A methodological assessment of diurnal variability of peak flow as a basis for comparing different inhaled steroid formulations. J Allergy Clin Immunol 1996; 98: 555-562.
37. López-Viña A, del Castillo-Arévalo E. Influence of peak expiratory flow monitoring on an asthma self-management education programme. Respir Med 2000; 94: 760-766.
38. Aggarwal AN, Gupta D, Kumar V, et al. Assessment of diurnal variability of peak expiratory flow in stable asthmatics. J Asthma 2002; 39: 487-491.
39. ten Hacken NH, van der Vaart T, van der Mark TW, et al. Exhaled nitric oxide is higher both at day and night in subjects with nocturnal asthma. Am J Respir Crit Care Med 1998; 158: 902-907.
40. Thamrin C, Taylor DR, Jones SL, et al. Variability of lung function predicts loss of asthma control following withdrawal of inhaled corticosteroid treatment. Thorax 2010; 65: 403-408.
41. Shaw DE, Berry MA, Thomas M, et al. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med 2007; 176: 231-237.
42. McNicholl DM, Stevenson M, McGarvey LP, et al. The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma. Am J Respir Crit Care Med 2012; 186: 1102-1108.